Ion News and Research

RSS

Scorpion’s toxins can reduce heart bypass failures: Research

A toxin found in the venom of the Central American bark scorpion (Centruroides margaritatus) could hold the key to reducing heart bypass failures, according to research from the University of Leeds.

22 Oct 2010

Inspire presents data on denufosol therapy for cystic fibrosis at NACFC conference

Inspire Pharmaceuticals, Inc. announced today that data will be presented on denufosol tetrasodium, an investigational therapy for cystic fibrosis (CF), during oral and poster presentations at the 24th Annual North American Cystic Fibrosis Conference (NACFC) October 21-23, 2010 in Baltimore, Maryland.

22 Oct 2010

Researchers identify new mechanism that could help develop effective chemotherapy drug

Information on proteins is critical for understanding how cells function in health and disease. But while regular proteins are easy to extract and study, it is far more difficult to gather information about membrane proteins, which are responsible for exchanging elements essential to our health, like copper, between a cell and its surrounding tissues.

19 Oct 2010

Novel bioelectric signals can cause stem cells to trigger melanoma-like growth in pigment cells

Biologists at Tufts University School of Arts and Sciences have discovered that a change in membrane voltage in newly identified "instructor cells" can cause stem cells' descendants to trigger melanoma-like growth in pigment cells. The Tufts team also found that this metastatic transformation is due to changes in serotonin transport. The discovery could aid in the prevention and treatment of diseases like cancer and vitiligo as well as birth defects.

19 Oct 2010

Vertex commences VX-770 and VX-809 combination Phase 2a clinical trial for cystic fibrosis

Vertex Pharmaceuticals Incorporated today announced the initiation of a Phase 2a clinical trial that will evaluate multiple combinations of VX-770 and VX-809, investigational oral cystic fibrosis transmembrane conductance regulator (CFTR) modulators for the treatment of cystic fibrosis (CF). The trial is designed to evaluate the safety and tolerability of VX-809 dosed alone for 14 days followed by dosing of VX-809 in combination with VX-770 for 7 days.

18 Oct 2010

Pericytes regulate blood-brain barrier

While the blood-brain barrier (BBB) protects the brain from harmful chemicals occurring naturally in the blood, it also obstructs the transport of drugs to the brain. In an article in Nature scientists at the Swedish medical university Karolinska Institutet now present a potential solution to the problem. The key to the BBB is a cell-type in the blood vessel walls called pericytes, and the researchers hope that their findings will one day contribute to new therapies for diseases like Alzheimer's and stroke.

15 Oct 2010

Scientists find pericytes regulate blood-brain barrier

14 Oct 2010

Research may pave way to cure cystic fibrosis

A University of Missouri researcher believes his latest work moves scientists closer to a cure for cystic fibrosis, one of the world's most common fatal genetic diseases.

13 Oct 2010

Class action lawsuit against DePuy Orthopaedics

The preeminent law office of Nurenberg, Paris, Heller & McCarthy has filed a class action lawsuit against Johnson & Johnson's artificial joint replacement company DePuy Orthopaedics, Inc., on behalf of clients who suffered damages resulting from the company's now-recalled hip replacement device. (Case No. 1:10CV02222, U.S. District Court, Northern District of Ohio, Eastern Division)

11 Oct 2010

Gymnemic acid nanocrystals could help develop soluble drug compounds

Researchers in India have demonstrated that producing nanoscopic crystals of a pharmaceutical product can allow the medication to be absorbed by the gut even if the drug is not soluble in water.

7 Oct 2010

GE Healthcare launches first human cellular assay product

Geron Corporation today announced that GE Healthcare has launched the first human cellular assay product for use in drug discovery and toxicity screening, developed under a license and alliance agreement between the two companies.

5 Oct 2010

Scientists use directed light to cause arrhythmia in genetically modified mice

Scientists at the University of Bonn have altered cardiac muscle cells to make them controllable with light. They were thus able to use directed light to cause conditions such as arrhythmia in genetically modified mice. The method opens up completely new possibilities for researching the development of such arrhythmias. The study will be published in the upcoming edition of "Nature Methods".

5 Oct 2010

Life Technologies acquires Ion Torrent for $375 million

Life Technologies Corporation, a provider of innovative life science solutions, today announced that it has completed the previously announced acquisition of Ion Torrent for $375 million in cash and stock. In addition, sellers are entitled to additional consideration upon the achievement of certain milestones.

4 Oct 2010

Welch Allyn launches Connex ProBP handheld automated digital blood pressure device

Welch Allyn, a leading global provider of frontline medical products and solutions, today introduced the Connex® ProBP™ 3400, an automated digital blood pressure device designed to fit in the palm of the hand. Borrowing Welch Allyn SureBP™ technology from the company's multiparameter vital signs devices, the Connex ProBP delivers fast, accurate blood pressure readings with the durability of Welch Allyn's popular hospital-grade vital signs devices.

4 Oct 2010

Scientists use NMR technology to improve protein purification in drug development

The purification of drug components is a large hurdle facing modern drug development. This is particularly true of drugs that utilize proteins, which are notoriously difficult to separate from other potentially deadly impurities. Scientists within the Center for Biotechnology and Interdisciplinary Studies (CBIS) at Rensselaer Polytechnic Institute are using nuclear magnetic resonance (NMR) to understand and improve an important protein purification process.

30 Sep 2010

New RTCA Cardio Instrument monitors real-time cardiomyocyte beating and cellular events

Roche announced today that it had launched the RTCA Cardio Instrument, the latest member of the xCELLigence product family. The RTCA Cardio Instrument is a medium throughput cell analyzer that utilizes impedance readings to monitor cardiac beating and cellular events in real time.

From Roche Sequencing and Life Science 29 Sep 2010

Researchers identify mechanism that makes bacteria to resist antibiotics

A research team led by Edward Yu of Iowa State University and the Ames Laboratory has discovered the crystal structures of pumps that remove heavy metal toxins from bacteria, making them resistant to antibiotics.

24 Sep 2010

Covidien launches Puritan Bennett 560 ventilator in Europe

Covidien, a leading global healthcare products company and recognized innovator in mechanical ventilation and respiratory care devices, today announced that the Puritan Bennett™ 560 ventilator is now available in Europe. The Puritan Bennett 560 ventilator is compact and portable, weighing just 4.5 kg. This lightweight device provides mobile respiratory support, enabling ventilated adult and pediatric patients to pursue regular activities with peace of mind.

23 Sep 2010

Evotec AG collaborates with Almirall for ion channel validation in respiratory diseases

Evotec AG today announced that it has entered into a collaboration with Almirall S.A. to identify small molecule modulators of an ion channel target, selected by Almirall, involved in respiratory diseases.

23 Sep 2010

TAXUS Element Stent has comparable levels of TLR and late loss in diabetic and non-diabetic patients

Boston Scientific Corporation today announced results from an analysis of 1,166 patients from its PERSEUS clinical program comparing the performance of the TAXUS® Element™ Paclitaxel-Eluting Coronary Stent System in diabetic versus non-diabetic patients. Results demonstrated that despite the known increased risk of restenosis for diabetics versus non-diabetics in patients undergoing coronary revascularization, the TAXUS Element Stent had comparable levels of target lesion revascularization (TLR) and late loss in both diabetic and non-diabetic patients.

23 Sep 2010

Ion News and Research

Scorpion’s toxins can reduce heart bypass failures: Research

Inspire presents data on denufosol therapy for cystic fibrosis at NACFC conference

Researchers identify new mechanism that could help develop effective chemotherapy drug

Novel bioelectric signals can cause stem cells to trigger melanoma-like growth in pigment cells

Vertex commences VX-770 and VX-809 combination Phase 2a clinical trial for cystic fibrosis

Pericytes regulate blood-brain barrier

Scientists find pericytes regulate blood-brain barrier

Research may pave way to cure cystic fibrosis

Class action lawsuit against DePuy Orthopaedics

Gymnemic acid nanocrystals could help develop soluble drug compounds

GE Healthcare launches first human cellular assay product

Scientists use directed light to cause arrhythmia in genetically modified mice

Life Technologies acquires Ion Torrent for $375 million

Welch Allyn launches Connex ProBP handheld automated digital blood pressure device

Scientists use NMR technology to improve protein purification in drug development

New RTCA Cardio Instrument monitors real-time cardiomyocyte beating and cellular events

Researchers identify mechanism that makes bacteria to resist antibiotics

Covidien launches Puritan Bennett 560 ventilator in Europe

Evotec AG collaborates with Almirall for ion channel validation in respiratory diseases

TAXUS Element Stent has comparable levels of TLR and late loss in diabetic and non-diabetic patients

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News